Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). (Image courtesy of Nyxoah webpage)
Mont-Saint-Guibert (Belgium), September 27, 2024, 08:05 am CET / 2:05 am ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
- Share capital: EUR 5,907,711.21
- Total number of securities carrying voting rights: 34,389,015 (all ordinary shares)
- Total number of voting rights (= denominator): 34,389,015 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued: 2,040,231 (all granted subscription rights; this number excludes 643,394 subscription rights that were issued but not yet granted)
*
* *
Contact:
Nyxoah
Loic Moreau, CFO
IR@nyxoah.com
Attachment
Source: Nyxoah via GLOBE NEWSWIRE
